Skip to main content
Top
Published in: Diabetologia 12/2006

01-12-2006 | Article

Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women

Authors: Q. Qiao, The DECODE Study Group

Published in: Diabetologia | Issue 12/2006

Login to get access

Abstract

Aims/hypothesis

We estimated cardiovascular disease (CVD) mortality in individuals with the metabolic syndrome on the basis of different definitions.

Methods

We collaboratively analysed data from 4,715 men and 5,554 women, who were aged 30 to 89 years, had a maximum follow-up of 7 to 16 years, and were drawn from nine European population-based cohorts. Cox regression analysis with age as time scale was performed to estimate hazard ratio (HR) for mortality, adjusting for cohort, serum total cholesterol and smoking.

Results

The prevalence of the metabolic syndrome according to definitions of WHO, the National Cholesterol Education Program (NCEP), NCEP revised and the International Diabetes Federation (IDF) was 27.0%, 25.9%, 32.2% and 35.9% respectively in men and 19.7%, 23.4%, 28.5% and 34.1% respectively in women. The corresponding HRs (95% CIs) for CVD mortality were 2.09 (1.59–2.76), 1.74 (1.31–2.30), 1.72 (1.31–2.26) and 1.51 (1.15–1.99) in men, and 1.60 (1.01–2.51), 1.39 (0.89–2.18), 1.09 (0.70–1.69) and 1.53 (0.99–2.36) in women. The paired homogeneity test showed that in men the HR was higher with the WHO definition than with the IDF definition (p=0.03). In women the HR was lower with the revised NCEP definitions than with either the WHO (p=0.02) or the IDF (p=0.01) definitions. With a few exceptions, HRs for full definitions of the syndrome were not significantly different from those for their single components.

Conclusions/interpretation

Metabolic syndrome by the four definitions predicted CVD mortality in men, but the prediction was weak in women. Further research is required on the utility of definitions of the metabolic syndrome above and beyond that of its single components and in individual CVD risk stratification, particularly with regard to sex difference in the prediction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
2.
go back to reference World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report No. 99.2. WHO, Geneva World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report No. 99.2. WHO, Geneva
3.
go back to reference Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443PubMedCrossRef Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443PubMedCrossRef
4.
go back to reference Adult Treatment Panel III (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 Adult Treatment Panel III (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
5.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
6.
go back to reference Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13–e18PubMedCrossRef Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13–e18PubMedCrossRef
7.
go back to reference Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25–26 August 2002, Washington, DC. Diabetes Care 26:933–939PubMed Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25–26 August 2002, Washington, DC. Diabetes Care 26:933–939PubMed
8.
go back to reference American College of Endocrinology Task Force on the Insulin Resistance Syndrome (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252 American College of Endocrinology Task Force on the Insulin Resistance Syndrome (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252
9.
go back to reference Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef
10.
go back to reference Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480PubMedCrossRef Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480PubMedCrossRef
11.
go back to reference Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMed Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMed
12.
go back to reference Lawlor DA, Smith GD, Ebrahim S (2006) Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study. Diabetologia 49:41–48PubMedCrossRef Lawlor DA, Smith GD, Ebrahim S (2006) Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study. Diabetologia 49:41–48PubMedCrossRef
13.
go back to reference The DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621CrossRef The DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621CrossRef
14.
go back to reference The DECODE Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Br Med J 317:371–375 The DECODE Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Br Med J 317:371–375
15.
go back to reference The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all-cause, cardiovascular and non-cardiovascular disease? Diabetes Care 26:688–696 The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all-cause, cardiovascular and non-cardiovascular disease? Diabetes Care 26:688–696
16.
go back to reference The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef
17.
go back to reference The DECODE Study Group (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076CrossRef The DECODE Study Group (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076CrossRef
18.
go back to reference The DECODE Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256CrossRef The DECODE Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256CrossRef
19.
go back to reference Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2:121–145PubMed Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2:121–145PubMed
20.
go back to reference Davidson AC, Hinkley DV (1997) Bootstrap methods and their application. Cambridge University Press, Cambridge Davidson AC, Hinkley DV (1997) Bootstrap methods and their application. Cambridge University Press, Cambridge
21.
go back to reference Bonora E, Kiechl S, Willeit J et al (2003) Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26:1251–1257PubMed Bonora E, Kiechl S, Willeit J et al (2003) Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26:1251–1257PubMed
22.
go back to reference Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257PubMedCrossRef Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257PubMedCrossRef
23.
go back to reference Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed
24.
go back to reference Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef
25.
go back to reference Scuteri A, Najjar SS, Morrell CH, Lakatta EG (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28:882–887PubMed Scuteri A, Najjar SS, Morrell CH, Lakatta EG (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28:882–887PubMed
26.
go back to reference Dekker JM, Girman C, Rhodes T et al (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666–673PubMedCrossRef Dekker JM, Girman C, Rhodes T et al (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666–673PubMedCrossRef
27.
go back to reference Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2006) Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. Diabetologia 49:56–65PubMedCrossRef Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2006) Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. Diabetologia 49:56–65PubMedCrossRef
28.
go back to reference Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L (2006) Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. Br Med J 332:878–882CrossRef Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L (2006) Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. Br Med J 332:878–882CrossRef
29.
go back to reference Kurl S, Laukkanen JA, Niskanen L et al (2006) Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37:806–811PubMedCrossRef Kurl S, Laukkanen JA, Niskanen L et al (2006) Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37:806–811PubMedCrossRef
30.
go back to reference Butler J, Rodondi N, Zhu Y et al (2006) Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47:1595–1602PubMedCrossRef Butler J, Rodondi N, Zhu Y et al (2006) Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47:1595–1602PubMedCrossRef
31.
go back to reference Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis [Epub ahead of print] Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis [Epub ahead of print]
32.
go back to reference Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097PubMedCrossRef Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097PubMedCrossRef
33.
go back to reference McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390PubMed McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390PubMed
34.
go back to reference Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef
35.
go back to reference Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867PubMed Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867PubMed
36.
go back to reference Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385PubMedCrossRef Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385PubMedCrossRef
37.
go back to reference Takeuchi H, Saitoh S, Takagi S et al (2005) Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men — the Tanno and Sobetsu Study. Hypertens Res 28:203–208PubMedCrossRef Takeuchi H, Saitoh S, Takagi S et al (2005) Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men — the Tanno and Sobetsu Study. Hypertens Res 28:203–208PubMedCrossRef
38.
go back to reference Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314PubMedCrossRef Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314PubMedCrossRef
39.
go back to reference Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983PubMed Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983PubMed
Metadata
Title
Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women
Authors
Q. Qiao
The DECODE Study Group
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0438-6

Other articles of this Issue 12/2006

Diabetologia 12/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.